• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials.

作者信息

Weisnagel S John

机构信息

Department of Endocrinology and Nephrology, Faculty of Medicine, Diabetes Research Unit, CHU Research Centre, Laval University, Québec, Canada.

出版信息

Ann Transl Med. 2018 May;6(10):194. doi: 10.21037/atm.2018.03.29.

DOI:10.21037/atm.2018.03.29
PMID:29951516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5994526/
Abstract
摘要

相似文献

1
The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials.胰高血糖素样肽-1受体激动剂在2型糖尿病心血管疾病预防中的作用：来自最新临床试验的证据
Ann Transl Med. 2018 May;6(10):194. doi: 10.21037/atm.2018.03.29.
2
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
3
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。
Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.
4
[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].基于胰高血糖素样肽-1受体激动剂的抗糖尿病治疗对2型糖尿病患者心血管风险的影响
Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18.
5
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者的心血管风险降低：这是一类药物的作用吗？
Curr Cardiol Rep. 2018 Sep 26;20(11):113. doi: 10.1007/s11886-018-1051-2.
6
Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.2型糖尿病患者中胰高血糖素样肽-1受体激动剂心血管安全性的最新进展。一项随机对照试验的混合治疗比较荟萃分析。
Heart Lung Circ. 2018 Nov;27(11):1301-1309. doi: 10.1016/j.hlc.2018.03.018. Epub 2018 Mar 29.
7
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者体重减轻的影响：一项系统评价与混合治疗比较的Meta分析
PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.
8
Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?
Expert Opin Drug Saf. 2015 Jun;14(6):801-5. doi: 10.1517/14740338.2015.1034106. Epub 2015 Apr 20.
9
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.胰高血糖素样肽受体激动剂和二肽基肽酶-4抑制剂治疗糖尿病：临床试验综述
Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414.
10
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.2型糖尿病中胰高血糖素样肽-1受体激动剂：随机临床试验的荟萃分析。
Eur J Endocrinol. 2009 Jun;160(6):909-17. doi: 10.1530/EJE-09-0101. Epub 2009 Mar 24.

引用本文的文献

1
Evaluation of Serum Glucagon-Like Peptide 1 and Vitamin D Levels in Elderly Patients with Bone Fractures.评估老年骨折患者血清胰高血糖素样肽 1 和维生素 D 水平。
Med Princ Pract. 2020;29(3):219-224. doi: 10.1159/000502132. Epub 2019 Jul 17.

本文引用的文献

1
Incretin hormones: Their role in health and disease.肠降血糖素：它们在健康和疾病中的作用。
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129.
2
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者的心血管结局：一项荟萃分析。
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.
3
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).卡格列净用于心血管事件的一级和二级预防：来自 CANVAS 项目（卡格列净心血管评估研究）的结果。
Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.
4
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病管理中的作用。
Can J Diabetes. 2017 Oct;41(5):517-523. doi: 10.1016/j.jcjd.2017.08.241.
5
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽对2型糖尿病患者心血管结局的影响。
N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.
6
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.在研究每周使用肠降血糖素对糖尿病患者心血管影响的心血管事件研究（REWIND）试验中，参与者的设计和基线特征。
Diabetes Obes Metab. 2018 Jan;20(1):42-49. doi: 10.1111/dom.13028. Epub 2017 Jul 14.
7
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.GLP-1 受体激动剂与 SGLT2 抑制剂联合治疗。
Diabetes Obes Metab. 2017 Oct;19(10):1353-1362. doi: 10.1111/dom.12982. Epub 2017 Jun 7.
8
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.阿必鲁肽治疗2型糖尿病：HARMONY 3期试验的综合安全性分析
Diabetes Res Clin Pract. 2017 Apr;126:230-239. doi: 10.1016/j.diabres.2017.02.017. Epub 2017 Feb 20.
9
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
10
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.